Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.53 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.53 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.53 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16562116 | 0.89 | CHRM5 (0.56) | SMN1; SMN2ALDH1A1POLBMAPTPLAAT3 | |
| SCHEMBL17919369 | 0.83 | SMN1; SMN2 (0.77) | SMN1; SMN2ALDH1A1MAPTPLAAT3PLAAT5 | |
| SCHEMBL16562105 | 0.83 | ALDH1A1 (0.72) | SMN1; SMN2ALDH1A1POLBMAPTPLAAT3 | |
| SCHEMBL16562220 | 0.82 | ALDH1A1 (0.70) | SMN1; SMN2ALDH1A1POLBMAPTPLAAT3 | |
| SCHEMBL16562217 | 0.78 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1POLBMAPTPLAAT3 | |
| SCHEMBL16562061 | 0.77 | NPC1 (0.70) | SMN1; SMN2ALDH1A1POLBKMT2ANPC1 | |
| SCHEMBL16562268 | 0.77 | NPC1 (0.70) | SMN1; SMN2ALDH1A1POLBKMT2ANPC1 | |
| SCHEMBL10516281 | 0.76 | SMN1; SMN2 (0.71) | SMN1; SMN2ALDH1A1MAPTPLAAT3PLAAT5 | |
| SCHEMBL16562114 | 0.75 | NPC1 (0.67) | SMN1; SMN2ALDH1A1POLBPLAAT3PLAAT5 | |
| SCHEMBL16562144 | 0.75 | NPC1 (0.64) | SMN1; SMN2ALDH1A1POLBMAPTPLAAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| WO-2015035051-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | NCOA4, SREBF1, ACOX1 | SMN1; SMN2 3069/4885ALDH1A1 88/4885POLB 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.